tiprankstipranks
Takeda Pharmaceutical Co Ltd (DE:TKD)
FRANKFURT:TKD
Germany Market
TKD
Takeda Pharmaceutical Co
RESEARCH TOOLSreports

Takeda Pharmaceutical Co (TKD) Stock Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

TKD Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Takeda
Pharmaceutical Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TKD Stock 12 Month Forecast

Average Price Target

€35.63
▲(45.74% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Takeda Pharmaceutical Co in the last 3 months. The average price target is €35.63 with a high forecast of €37.25 and a low forecast of €34.01. The average price target represents a 45.74% change from the last price of €24.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","38":"€38","25.25":"€25.3","29.5":"€29.5","33.75":"€33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.2531,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.6334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€35.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.0137,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,25.25,29.5,33.75,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,28.342546153846154,29.08509230769231,29.827638461538463,30.57018461538462,31.31273076923077,32.055276923076924,32.79782307692308,33.54036923076923,34.282915384615386,35.02546153846154,35.76800769230769,36.51055384615385,{"y":37.2531,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,28.217953846153847,28.835907692307693,29.45386153846154,30.071815384615388,30.689769230769233,31.30772307692308,31.925676923076924,32.543630769230774,33.16158461538462,33.779538461538465,34.39749230769231,35.015446153846156,{"y":35.6334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,28.09336153846154,28.58672307692308,29.080084615384617,29.573446153846156,30.066807692307695,30.560169230769233,31.05353076923077,31.546892307692307,32.040253846153846,32.53361538461539,33.02697692307692,33.52033846153846,{"y":34.0137,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.939,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.307,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.795,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.17,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.814,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.287,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.486,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.866,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.615,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.66,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€37.25Average Price Target€35.63Lowest Price Target€34.01
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:TKD
Miki Sogi
Bernstein
Bernstein
€37.25
Buy
52.36%
Upside
Assigned
07/07/26
Takeda Pharmaceutical Co (TKPHF) Receives a Buy from Bernstein
Morgan Stanley Analyst forecast on DE:TKD
Shinichiro Muraoka
Morgan Stanley
Morgan Stanley
€33.47→€34.01
Buy
39.12%
Upside
Reiterated
06/03/26
Takeda Pharmaceutical Co (TKPHF) Gets a Buy from Morgan Stanley
Macquarie Analyst forecast on DE:TKD
Unknown Analyst
Macquarie
Not Ranked
Macquarie
€28.07→€27
Buy
10.41%
Upside
Reiterated
10/14/25
Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)
Bank of America Securities Analyst forecast on DE:TKD
Koichi Mamegano
Bank of America Securities
Bank of America Securities
€29.69
Buy
21.45%
Upside
Reiterated
09/08/25
Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:TKD
Miki Sogi
Bernstein
Bernstein
€37.25
Buy
52.36%
Upside
Assigned
07/07/26
Takeda Pharmaceutical Co (TKPHF) Receives a Buy from Bernstein
Morgan Stanley Analyst forecast on DE:TKD
Shinichiro Muraoka
Morgan Stanley
Morgan Stanley
€33.47→€34.01
Buy
39.12%
Upside
Reiterated
06/03/26
Takeda Pharmaceutical Co (TKPHF) Gets a Buy from Morgan Stanley
Macquarie Analyst forecast on DE:TKD
Unknown Analyst
Macquarie
Not Ranked
Macquarie
€28.07→€27
Buy
10.41%
Upside
Reiterated
10/14/25
Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)
Bank of America Securities Analyst forecast on DE:TKD
Koichi Mamegano
Bank of America Securities
Bank of America Securities
€29.69
Buy
21.45%
Upside
Reiterated
09/08/25
Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Takeda Pharmaceutical Co

3 Months
Koichi MameganoBank of America Securities
Success Rate
4/7 ratings generated profit
57%
Average Return
+3.79%
Copying Koichi Mamegano's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +3.79% per trade.
1 Year
Koichi MameganoBank of America Securities
Success Rate
7/7 ratings generated profit
100%
Average Return
+19.54%
Copying Koichi Mamegano's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +19.54% per trade.
2 Years
Koichi MameganoBank of America Securities
Success Rate
7/7 ratings generated profit
100%
Average Return
+25.09%
Copying Koichi Mamegano's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TKD Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
1
2
2
3
2
Hold
1
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
3
3
4
2
In the current month, TKD has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TKD average Analyst price target in the past 3 months is 35.63.
Each month's total comprises the sum of three months' worth of ratings.

TKD Financial Forecast

TKD Earnings Forecast

Next quarter’s earnings estimate for TKD is €0.28 with a range of €0.25 to €0.31. The previous quarter’s EPS was -€0.08. TKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TKD has Performed in-line its overall industry.
Next quarter’s earnings estimate for TKD is €0.28 with a range of €0.25 to €0.31. The previous quarter’s EPS was -€0.08. TKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TKD has Performed in-line its overall industry.

TKD Sales Forecast

Next quarter’s sales forecast for TKD is €6.25B with a range of €5.98B to €6.54B. The previous quarter’s sales results were €5.93B. TKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TKD has Performed in-line its overall industry.
Next quarter’s sales forecast for TKD is €6.25B with a range of €5.98B to €6.54B. The previous quarter’s sales results were €5.93B. TKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TKD has Performed in-line its overall industry.

TKD Stock Forecast FAQ

What is DE:TKD’s average 12-month price target, according to analysts?
Based on analyst ratings, Takeda Pharmaceutical Co Ltd’s 12-month average price target is 35.63.
    What is DE:TKD’s upside potential, based on the analysts’ average price target?
    Takeda Pharmaceutical Co Ltd has 45.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Takeda Pharmaceutical Co Ltd a Buy, Sell or Hold?
          Takeda Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Takeda Pharmaceutical Co Ltd’s share price target?
            The average share price target for Takeda Pharmaceutical Co Ltd is 35.63. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €37.25 ,and the lowest forecast is €34.01. The average share price target represents 45.74% Increase from the current price of €24.45.
              What do analysts say about Takeda Pharmaceutical Co Ltd?
              Takeda Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Takeda Pharmaceutical Co Ltd?
                To buy shares of DE:TKD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.